NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

vmlg17,

Any validation gives hope that this therapy and Direct will be utilized beyond a subset of patients since mesenchymal subtype is found at some point in the vast majority of cancers. The valuation banter is just another way to create doubt about the true implications of this therapy. Potential use of this basic format in regenerative medicine is also in the mix and has been since the early understanding of the MO of DCs in general and Direct specifically began to come to light.

The SAB is going to be looking at how to best move forward with the entire underlying potential of the basic modality of this treatment. The fact that Linda's other companies focus on stem cell research and have a planned presence at Sawston points to some pretty important crossover implications that is related to the potential success of the DCVax platform.

Pyrrhonian actually led me to do research in regenerative medicine with regard to heart muscle repair in ischemic (low oxygen) regions when he was talking about the potential of another company's product. His comments were in regard to damage repair mechanisms that can be deployed after a heart attack and this crisscrossed with notes I had taken earlier related to NWBO. When I researched this apparent crossover application I realized that NWBO is on to something way bigger than almost anyone can possibly fathom.